Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. Chief Financial Officer Renee Gaeta reported an open‑market sale of 17,672 shares of Common Stock at $4.94 per share. According to the disclosure, this was a required “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of 32,856 RSU-based shares.
The filing notes that the sale does not represent a discretionary trade by the executive. After the transaction, Gaeta directly holds 113,753 shares of Outset Medical Common Stock, indicating she retains a substantial equity stake following the tax‑related sale.
Outset Medical, Inc. reported the results of its Annual Meeting of Stockholders held on June 4, 2026 via virtual audio webcast. As of the April 9, 2026 record date, 18,529,233 shares of common stock were outstanding and entitled to vote, and 13,890,864 shares were represented at the meeting, establishing a quorum.
Stockholders elected Brent D. Lang and Karen Prange as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers. In addition, stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
OM submitted a Form 144 notice concerning Common Stock. The filing shows 32,856 shares tied to the settlement of vested restricted stock units on 06/03/2026, described as equity compensation for services rendered. The broker listed is Morgan Stanley Smith Barney LLC.
Outset Medical, Inc. reported a leadership change as Executive Vice President, R&D, Operations and Service, Marc Nash, has decided to depart the company. His role will end effective June 5, 2026, as he pursues other professional opportunities.
The company stated that Mr. Nash’s departure is not due to any dispute or disagreement with the company or its management, framing this as a voluntary transition rather than a conflict-driven exit.
Outset Medical, Inc. director and Chair and CEO Leslie Trigg reported an open-market sale of 3,445 shares of Common Stock at $3.70 per share. According to the footnotes, this was a required sale to cover tax withholding obligations tied to the vesting of 9,319 RSU-based shares and did not represent a discretionary trade.
After the sale, Trigg held 98,874 Common Stock shares directly, along with 584 shares held indirectly through the Trigg Family Trust and 41,666 shares held indirectly through the Trigg 2002 Rev Trust, all as of May 15, 2026.
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,582 shares of common stock at $3.70 per share. According to the footnote, this was a required “sell to cover” transaction to pay tax withholding on the vesting of 4,277 RSU shares and was not a discretionary trade. After the sale, Nash directly holds 38,393 shares of Outset Medical common stock.
Outset Medical, Inc. General Counsel John L. Brottem reported an open-market sale of 2,638 shares of Common Stock at $3.70 per share. According to the footnotes, this was a required "sell to cover" transaction to satisfy tax withholding obligations tied to the vesting of 5,033 RSU-based shares and is not a discretionary trade. After this tax-related sale, Brottem directly holds 30,277 shares of Common Stock. A separate footnote notes a correction to a previously reported 2,842-share tax-related sale, revising it to 2,862 shares due to an administrative error.
Outset Medical, Inc. ownership disclosure: BML Investment Partners, L.P. reports beneficial ownership of 2,519,706 shares of common stock, representing 13.6% of the class. The filing states shared voting and dispositive power of 2,519,701 shares and names Braden M. Leonard as indirect owner via BML Capital Management, LLC.
Outset Medical, Inc. disclosed that investment entity BML Investment Partners, L.P., associated with major holder Leonard Braden Michael, acquired 323,000 shares of common stock at $5.00 per share. The shares were assigned upon expiration of short June 2026 put options held by the reporting owner.
Following this option assignment, BML Investment Partners, L.P. indirectly holds 2,519,701 shares of Outset Medical common stock. Mr. Leonard, as managing member of BML Capital Management, LLC, exercises voting and investment control over the fund’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
OM reported a Section 144 notice describing restricted stock units that vested and were settled into 5,033 shares on 05/15/2026. The filing also shows a prior sale of 2,862 shares on 02/17/2026 attributed to John Brottem. The transaction is listed as equity compensation for services rendered.